Overview
- Editors:
-
-
Anthony D. Whetton
-
Leukaemia Research Fund Cellular Development Unit, UMIST, Manchester, England
-
John Gordon
-
The Medical School, University of Birmingham, Birmingham, England
Access this book
Other ways to access
Table of contents (15 chapters)
-
Front Matter
Pages i-xxiii
-
- Anne-Marie O’Farrell, Taisei Kinoshita, Atsushi Miyajima
Pages 1-40
-
- Andrew N. J. McKenzie, Andrew W. Heath
Pages 41-50
-
-
-
- Caroline A. Evans, Andrew Pierce
Pages 99-120
-
-
- Rachel S. Chapman, Christopher D. Gregory, Caroline Dive
Pages 151-201
-
- Mike Salmon, Darrell Pilling, Clair Mappin, Arne N. Akbar
Pages 203-215
-
- Ana Cumano, Barbara L. Kee, Isabelle Godin, Françoise Dieterlen-Lièvre, C. J. Paige
Pages 217-239
-
- Jacques Banchereau, Pierre Garrone, Yong-Jun Liu
Pages 241-262
-
- Christophe Caux, Jacques Banchereau
Pages 263-301
-
-
- Jan Tavernier, Geert Plaetinck, Yves Guisez, Jose van der Heyden, Johan Kips, Renaat Peleman et al.
Pages 321-361
-
- Ian K. McNiece, Robert A. Briddell
Pages 363-379
-
- Andrew Weaver, Nydia G. Testa
Pages 381-413
-
Back Matter
Pages 415-419
About this book
Historically, the field of hematopoietic growth factor research began with the work of Carnot and Deflandre-in 1906 they suggested that the rate of erythropoiesis is regulated by a humoral factor found in the blood, namely, erythropoietin. From this comparatively early start, accelerating progress has been made in erythropoietin research, which demon strates the general trends in this field of study. Erythropoietin was purified to homogeneity by 1977 (from enormous quantities of urine from aplastic anemia patients). Subsequently, the gene for erythropoietin has been cloned (1985), and massive quantities of this growth factor have been produced for clinical trials (late 1980s onward). Erythropoietin has become established as a pharmaceutical product of great value in the treatment of a number of diseases, most notably chronic renal failure. Once the ligand had been cloned, interest turned to the erythropoietin receptor, which was cloned in 1989. Since then, structure/ function studies have been performed on receptor mutants, cellular signaling events down stream from the occupied receptor have been identified, and the specific producer cell types and molecular stimuli for erythropoietin production have been thoroughly investigated, as has the regulation of erythropoietin gene transcription. This schedule of events since the 1970s typifies that seen for a number of hematopoietic growth factors. Along the way, the hematopoietic growth factors have been recognized as members of the cytokine family of signaling molecules that are important in a number of different physiological and patholog ical situations (see below).
Reviews
`Thoroughly recommended as a valuable source of information for a variety of specialists.'
Comparative Haematology International, 1997
Editors and Affiliations
-
Leukaemia Research Fund Cellular Development Unit, UMIST, Manchester, England
Anthony D. Whetton
-
The Medical School, University of Birmingham, Birmingham, England
John Gordon
